The Spanish Competition Authority unconditionally clears a pharmaceutical merger despite significant horizontal overlaps because in the given market potential supply problems are external to the market competitors (Grifols / Biotest)
Grifols, SA acquires exclusive control of Biotest AG.*
On 2 March 2022, the CNMC authorised Grifols, S.A. to acquire indirect exclusive control of Biotest AG in phase one.
Grifols is a Spanish company involved in the research, development,
Access to this article is restricted to subscribers
Already Subscribed? Sign-in
Access to this article is restricted to subscribers.
Read one article for free
Sign-up to read this article for free and discover our services.